Botulinum Toxin Injection for Retrograde Cricopharyngeal Dysfunction: A Prospective Cohort Study.
Abstract
[OBJECTIVES] Retrograde Cricopharyngeal Dysfunction (RCPD) is treated by botulinum toxin (BTX) injection into the cricopharyngeus. This prospective study compares the effectiveness and side effects of operating room (OR) and in-office (IO) injections.
[METHODS] Patients over 18 years of age with inability to burp, abdominal, thoracic, or cervical gurgling sounds, bloating, and excessive flatulence were diagnosed with RCPD and included in the study. Injections were performed in the OR (80U) or IO (30U) by the senior author. An RCPD questionnaire quantifying major and minor symptoms on a Likert scale, Eating Assessment Tool-10 (EAT-10), and Generalized Anxiety Score-7 (GAD-7), were completed preinjection; at 1, 2, and 3 weeks; and 3 months postoperatively. Linear mixed models were used to analyze effects of BTX injection on RCPD symptoms, the EAT-10, and the GAD-7.
[RESULTS] 108 (55 M/53F) patients completed the pretreatment survey, 53 (31 OR vs. 22 IO) completed the 3-week follow-up, and 36 (22 OR vs. 14 IO) completed the 3-month questionnaire. Average posttreatment RCPD scores were significantly lower in both groups at 3 weeks and 3 months (p < 0.0001), There was no difference between IO or OR (p = 0.4924). GAD-7 scores were significantly lower in both groups at week 3 (p = 0.0018) and month 3 (p = 0.0012). Postinjection EAT-10 scores were significantly higher in OR compared with IO (p = 0.0379).
[CONCLUSION] OR and IO injections are equally effective in the treatment of RCPD. Postinjection dysphagia is more severe after the OR injections which may be related to higher doses of BTX used. General anxiety levels decrease with treatment.
[LEVEL OF EVIDENCE] 2 Laryngoscope, 134:4614-4619, 2024.
[METHODS] Patients over 18 years of age with inability to burp, abdominal, thoracic, or cervical gurgling sounds, bloating, and excessive flatulence were diagnosed with RCPD and included in the study. Injections were performed in the OR (80U) or IO (30U) by the senior author. An RCPD questionnaire quantifying major and minor symptoms on a Likert scale, Eating Assessment Tool-10 (EAT-10), and Generalized Anxiety Score-7 (GAD-7), were completed preinjection; at 1, 2, and 3 weeks; and 3 months postoperatively. Linear mixed models were used to analyze effects of BTX injection on RCPD symptoms, the EAT-10, and the GAD-7.
[RESULTS] 108 (55 M/53F) patients completed the pretreatment survey, 53 (31 OR vs. 22 IO) completed the 3-week follow-up, and 36 (22 OR vs. 14 IO) completed the 3-month questionnaire. Average posttreatment RCPD scores were significantly lower in both groups at 3 weeks and 3 months (p < 0.0001), There was no difference between IO or OR (p = 0.4924). GAD-7 scores were significantly lower in both groups at week 3 (p = 0.0018) and month 3 (p = 0.0012). Postinjection EAT-10 scores were significantly higher in OR compared with IO (p = 0.0379).
[CONCLUSION] OR and IO injections are equally effective in the treatment of RCPD. Postinjection dysphagia is more severe after the OR injections which may be related to higher doses of BTX used. General anxiety levels decrease with treatment.
[LEVEL OF EVIDENCE] 2 Laryngoscope, 134:4614-4619, 2024.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 2 | |
| 합병증 | cricopharyngeus
|
scispacy | 1 | ||
| 합병증 | abdominal
|
scispacy | 1 | ||
| 합병증 | cervical
|
scispacy | 1 | ||
| 약물 | RCPD
→ Retrograde Cricopharyngeal Dysfunction
|
scispacy | 1 | ||
| 약물 | Retrograde
|
scispacy | 1 | ||
| 약물 | [OBJECTIVES] Retrograde
|
scispacy | 1 | ||
| 약물 | 30U
|
scispacy | 1 | ||
| 약물 | BTX
→ botulinum toxin
|
scispacy | 1 | ||
| 약물 | [RESULTS] 108
|
scispacy | 1 | ||
| 약물 | [CONCLUSION] OR
|
scispacy | 1 | ||
| 질환 | inability to burp, abdominal, thoracic, or cervical gurgling
|
scispacy | 1 | ||
| 질환 | bloating
|
C0000731
Abdomen distended
|
scispacy | 1 | |
| 질환 | flatulence
|
C0016204
Flatulence
|
scispacy | 1 | |
| 질환 | Anxiety
|
C0003467
Anxiety
|
scispacy | 1 | |
| 질환 | Postinjection dysphagia
|
scispacy | 1 | ||
| 질환 | BTX
→ botulinum toxin
|
scispacy | 1 | ||
| 기타 | thoracic
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | IO injections are
|
scispacy | 1 |
MeSH Terms
Humans; Prospective Studies; Male; Female; Middle Aged; Treatment Outcome; Deglutition Disorders; Botulinum Toxins, Type A; Adult; Aged; Neuromuscular Agents; Surveys and Questionnaires; Pharyngeal Diseases; Botulinum Toxins
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.